Five months after it was blocked from discontinuing its brands 'Promus Premier' & 'Synergy' in India, Boston Scientific has approached NPPA...

The move is expected to preempt any shortages and ensure uninterrupted supply of a variety of high quality primary and revision knee implan...

Abbott had moved to withdraw Alpine citing that selling the product here was unviable after the maximum prices of all drug-eluting stents w...

The company asserted that its decision to withdraw Abbott was based on “low commercial uptake” and this was reflected in the sales figures ...

This year, domestic stent firms are aiming for 60 per cent of the market estimated to be Rs 1,200 crore now due to a drop in the average pr...

The government is expected to hold discussions to decide on these requests only in February, a year after it first capped prices of these l...

Abbott publicly announced intentions to stop global sales of dissolvable scaffold ‘Absorb’, which has been mired in controversy for risks r...

The companies sought to withdraw Abbott’s Xience Alpine and Absorb, and Medtronic’s Resolute Onyx stents after NPPA slashed their prices by...

Abbott is selling its drug eluting stents, including the Xience Alpine, for the equivalent of Rs 29,000 to Rs 33,000 in many European count...

The department of pharmaceuticals (DoP) said it had come across reports regarding shortage of coronary stents in the market and in hospital...

The move comes in the wake of various multinationals, including Abbott and Medtronic, seeking permission to withdraw some of their products...

It's not clear if firms can withdraw their products as the Department of Pharmaceuticals had recently prevented stent makers from taking th...